Clinical Trials Browser

Unknown × Lung Neoplasms × pembrolizumab × Clear all

NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Phase 1/2 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms

NCT04396457 2023-03-23

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

Phase 2 Unknown

Lung Neoplasms

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT03373955 2021-03-18

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03525782 2018-05-16

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms